Psychiatric and neurological disorders, such as depression, schizophrenia, Parkinson's disease and Alzheimer’s disease, inflict a huge amount of suffering on patients, as well as sorrow and despair on their relatives.
Hundreds of millions of people in the world suffer from psychiatric and neurological disorders. In spite of therapeutic progress, unfortunately, we remain a long way from fully understanding these diseases. There are immense unmet needs, not only for medication, but also for entire solutions in which therapy and updated information about the diseases are crucial factors.
Unfortunately, public awareness and the resources spent on curing and alleviating psychiatric and neurological disorders are a long way from matching the severity and consequences of the burden. These diseases place an enormous economic cost on society because they reduce or eliminate the patient’s ability to work.
At Lundbeck, we have made it our ambition to be the company that makes the biggest difference worldwide in the treatment of patients living with psychiatric and neurological disorders. Assuming this responsibility is an enormous task, but it is also an incredible joy when we succeed in developing a new and innovative drug that benefits people worldwide.
The target audience is a very broad group - from shareholders, authorities and healthcare professionals to Lundbeck employees, partners and the media.